Clinical impact of the systemic immune-inflammation index in non-small cell lung cancer patients
- PMID: 32617288
- PMCID: PMC7327326
- DOI: 10.21037/atm.2020.03.180
Clinical impact of the systemic immune-inflammation index in non-small cell lung cancer patients
Conflict of interest statement
Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.03.180). The author has no conflicts of interest to declare.
Comment on
-
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer.Ann Transl Med. 2019 Oct;7(20):572. doi: 10.21037/atm.2019.09.18. Ann Transl Med. 2019. PMID: 31807553 Free PMC article.
References
-
- Yuan C, Li N, Mao X, et al. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort. Thorac Cancer 2017;8:350-8. 10.1111/1759-7714.12454 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources